Researchers calculated the likelihood of achieving a BMD T-score of –2.5 or higher with denosumab based on baseline BMD. Minimum baseline BMD T-scores for denosumab success varied based on ...

every 3 months (n = 50) Placebo (n = 53) LS BMD: ↓0.6 vs 4.39% (p < 0.05) FN BMD: ↑0.4 vs ↓1.5% (p < 0.05) Hip BMD: ↑2.8 vs ↓0.12% (p < 0.05) 1-year follow-up: LS BMD stable vs ↓ (p ...

The findings highlight that oxidative stress not only worsens with CKD progression but may also play a significant role in ...

This review draws attention to a critical and often overlooked paradox in T2DM: patients may have normal or even high BMD, ...

every 3 months (n = 50) Placebo (n = 53) LS BMD: ↓0.6 vs 4.39% (p < 0.05) FN BMD: ↑0.4 vs ↓1.5% (p < 0.05) Hip BMD: ↑2.8 vs ↓0.12% (p < 0.05) 1-year follow-up: LS BMD stable vs ↓ (p ...